Major Depression Clinical Trial Landscape
Data updated: May 20, 2026
1,753 clinical trials tracked since 2008
Major Depressive Disorder (MDD), commonly known as depression, is a mood disorder that causes a persistent feeling of sadness and loss of interest, impacting how a person feels, thinks, and behaves. The clinical trial landscape for MDD is active, with 1,740 trials registered since 2008, and 350 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting. Activity is concentrated in Phase 2 trials, which account for 178 of the 699 total trials in this phase. Phase 1 trials account for 58 active trials out of 357 total, Phase 3 accounts for 77 active trials out of 467 total, and Phase 4 accounts for 73 active trials out of 388 total. Industry sponsorship is led by Neurocrine Biosciences, which currently has 6 active trials. Johnson & Johnson, Neumora Therapeutics, Inc., COMPASS Pathways, and Cybin IRL Limited each have 3 active trials.
358 active
/
1753 total (since 2008)
60
Phase 1 Active
358 total
184
Phase 2 Active
708 total
79
Phase 3 Active
471 total
74
Phase 4 Active
390 total
Top Industry Sponsors
Sorted by active Active Done Failed
Neurocrine Biosciences 6 5 0
Johnson & Johnson 4 33 10
Neumora Therapeutics, Inc. 3 2 0
COMPASS Pathways 3 2 0
Cybin IRL Limited 3 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT04777357 RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie n=380
NCT06029439 RECRUITING
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Neumora Therapeutics, Inc. n=1,000
NCT06308653 ACTIVE NOT RECRUITING
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute n=238
NCT06793397 RECRUITING
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited n=330
NCT07088380 RECRUITING
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Università Vita-Salute San Raffaele n=30
+ 466 more Phase 3 trials — see full database below
Major Depression — Trials Started by Year (last 10 years)
2016 78
2017 69
2018 88
2019 82
2020 69
2021 91
2022 87
2023 90
2024 100
2025 133
2026 66
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Neurocrine Biosciences 11
Johnson & Johnson 47
Neumora Therapeutics, Inc. 5
COMPASS Pathways 5
Cybin IRL Limited 4
Xenon Pharmaceuticals Inc. 4
Luye Pharma Group Ltd. 11
Alto Neuroscience 10
AbbVie 9
Axsome Therapeutics, Inc. 9
Active Trials by Phase
Phase 1 60
Phase 2 184
Phase 3 79
Phase 4 74
Enrollment Size Distribution
1-50 662
51-200 599
201-500 249
501-1k 118
1k+ 41
All Industry Sponsors
Sorted by active Active Done Failed
Neurocrine Biosciences 6 5 0
Johnson & Johnson 4 33 10
Neumora Therapeutics, Inc. 3 2 0
COMPASS Pathways 3 2 0
Cybin IRL Limited 3 1 0
Xenon Pharmaceuticals Inc. 3 1 0
Luye Pharma Group Ltd. 2 9 0
Alto Neuroscience 2 6 2
AbbVie 2 6 1
Axsome Therapeutics, Inc. 2 6 1
Syndeio Biosciences, Inc 2 4 1
Sirtsei Pharmaceuticals, Inc. 2 1 0
Soterix Medical 2 1 0
Enalare Therapeutics Inc. 2 0 0
Seaport Therapeutics 2 0 0
NCT04777357 RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie n=380
NCT06029439 RECRUITING
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Neumora Therapeutics, Inc. n=1,000
NCT06308653 ACTIVE NOT RECRUITING
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute n=238
NCT06793397 RECRUITING
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited n=330
NCT07088380 RECRUITING
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Università Vita-Salute San Raffaele n=30
NCT07227454 RECRUITING
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC n=258
NCT07573176 RECRUITING
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC n=600
NCT06559306 RECRUITING
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC n=752
NCT06564818 RECRUITING
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Cybin IRL Limited n=220
NCT06303739 ACTIVE NOT RECRUITING
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
University of North Carolina, Chapel Hill n=20
NCT06713616 RECRUITING
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Yale University n=400
NCT04984512 RECRUITING
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
Sunshine Lake Pharma Co., Ltd. n=600
NCT06860958 RECRUITING
Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Tanta University n=60
NCT06943573 NOT YET RECRUITING
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
Lakshmi N Yatham n=90
NCT06752759 RECRUITING
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Theresa Jacob, PhD, MPH n=40
NCT06966401 RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=850
NCT05054699 ACTIVE NOT RECRUITING
Electro-Magnetic Convulsive Therapies for Depression: a Non-inferiority Study
University of Sao Paulo n=100
NCT07263022 NOT YET RECRUITING
Cognitive Strategies in Early Psychosis 2
University of Minnesota n=24
NCT06963021 RECRUITING
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=200
NCT05552053 ACTIVE NOT RECRUITING
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
Cedars-Sinai Medical Center n=150
NCT05415397 ACTIVE NOT RECRUITING
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
Amsterdam UMC, location VUmc n=140
NCT06058039 ACTIVE NOT RECRUITING
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc. n=332
NCT06058013 ACTIVE NOT RECRUITING
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc. n=332
NCT07076407 RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Xenon Pharmaceuticals Inc. n=450
NCT07485595 NOT YET RECRUITING
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Tasly Pharmaceutical Group Co., Ltd n=180
NCT07507214 NOT YET RECRUITING
Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athletes With Co-morbid Depression and Concussion
University of Florida n=35
NCT07412756 RECRUITING
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company n=1,000
NCT07484217 RECRUITING
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc. n=508
NCT05174273 ACTIVE NOT RECRUITING
Neurocognitive Effects of FMT in MDD Patients With and Without IBS
Valerie Taylor n=133
NCT07196501 RECRUITING
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=550
NCT06781697 NOT YET RECRUITING
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
Sunnybrook Health Sciences Centre n=31
NCT06941844 ACTIVE NOT RECRUITING
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Definium Therapeutics US, Inc. n=149
NCT06605105 ENROLLING BY INVITATION
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Cybin IRL Limited n=468
NCT07204314 RECRUITING
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Takeda n=180
NCT07464886 RECRUITING
Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
University of Cincinnati n=160
NCT06830044 RECRUITING
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals n=500
NCT04041479 RECRUITING
Biomarker-guided rTMS for Treatment Resistant Depression
Weill Medical College of Cornell University n=348
NCT06922110 ENROLLING BY INVITATION
An Open-Label Study of Azetukalner in Major Depressive Disorder
Xenon Pharmaceuticals Inc. n=460
NCT05603104 RECRUITING
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Dr. Inge Winter n=1,254
NCT05711940 ACTIVE NOT RECRUITING
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways n=572
NCT04877197 RECRUITING
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
VA Office of Research and Development n=132
NCT05624268 ACTIVE NOT RECRUITING
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
COMPASS Pathways n=255
NCT07262008 NOT YET RECRUITING
Sustained Mood Improvement With Laughing Gas Exposure
Women's College Hospital n=120
NCT06911112 RECRUITING
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=200
NCT07227103 NOT YET RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression
NeuroRx, Inc. n=120
NCT07226232 NOT YET RECRUITING
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
VA Office of Research and Development n=240
NCT05474846 RECRUITING
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
M.D. Anderson Cancer Center n=188
NCT05944926 RECRUITING
Improving Outcomes in Depression in Primary Care in a Low Resource Setting
Harvard Medical School (HMS and HSDM) n=1,500
NCT06786624 RECRUITING
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences n=200
NCT05625360 RECRUITING
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
Wake Forest University Health Sciences n=160
NCT06273527 RECRUITING
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
University of California, San Diego n=128
NCT06775379 RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Xenon Pharmaceuticals Inc. n=450
NCT05973851 RECRUITING
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Dr. Inge Winter n=418
NCT06765057 RECRUITING
Effect of Probiotics "Psychobiotics" on Depression and Metabolic Syndrome in Saudi Arabia
Roaa Ahmed Alkreadees n=60
NCT06529029 RECRUITING
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Michigan State University n=30
NCT07153406 NOT YET RECRUITING
Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=220
NCT06698666 RECRUITING
Efficacy of Statins Among Major Depressive Disorder
Ain Shams University n=145
NCT07120880 NOT YET RECRUITING
Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
Assistance Publique - Hôpitaux de Paris n=184
NCT05186272 ACTIVE NOT RECRUITING
mHealth Mindfulness Intervention for Pregnant Black and Latina Women at Risk of Postpartum Depression
Kaiser Permanente n=600
NCT07084454 ENROLLING BY INVITATION
Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care
Cristiane Decat Bergerot, PhD n=350
NCT05850689 RECRUITING
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=470
NCT06958692 RECRUITING
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
CSPC Ouyi Pharmaceutical Co., Ltd. n=388
NCT06247839 RECRUITING
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi n=20
NCT06957704 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents
Federal University of São Paulo n=60
NCT03167905 ACTIVE NOT RECRUITING
CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery)
KK Women's and Children's Hospital n=881
NCT06891300 RECRUITING
Understanding and Treating Suicidal Ideation With Ketamine
The Royal's Institute of Mental Health Research n=36
NCT04116528 ACTIVE NOT RECRUITING
Opiate Suicide Study in Patients With Major Depression
Stanford University n=60
NCT06827431 NOT YET RECRUITING
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=770
NCT06765824 NOT YET RECRUITING
Transcranial Magnetic Stimulation in Patients with Dual Disorders
Cardenal Herrera University n=36
NCT05644301 RECRUITING
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
Universiteit Antwerpen n=240
NCT04011163 ACTIVE NOT RECRUITING
Vital Signs-Integrated Patient-Assisted Intravenous Opioid Analgesia for Post Surgical Pain
KK Women's and Children's Hospital n=40
NCT06590025 RECRUITING
Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=296
NCT06074250 RECRUITING
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
The Canadian College of Naturopathic Medicine n=100
NCT03423680 RECRUITING
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Korea Otsuka Pharmaceutical Co., Ltd. n=390
NCT03684447 ACTIVE NOT RECRUITING
Neural and Antidepressant Effects of Propofol
University of Utah n=48
NCT02568878 RECRUITING
Creatine for Depressed Male and Female Methamphetamine Users
Montana State University n=29
NCT07592689 RECRUITING
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Definium Therapeutics US, Inc. n=165
NCT04533529 COMPLETED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
Janssen Research & Development, LLC n=588
NCT05518149 TERMINATED
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Janssen Research & Development, LLC n=871
NCT03947827 COMPLETED
Minocycline as Adjunctive Treatment for Treatment Resistant Depression
Centre for Addiction and Mental Health n=76
NCT06635135 TERMINATED
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
Janssen Research & Development, LLC n=47
NCT06979544 COMPLETED
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Lipocine Inc. n=90
NCT06514742 TERMINATED
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
Janssen Research & Development, LLC n=101
NCT05550532 COMPLETED
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Janssen Research & Development, LLC n=444
NCT05233566 COMPLETED
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
Washington University School of Medicine n=32
NCT06360419 COMPLETED
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Axsome Therapeutics, Inc. n=346
NCT02783430 COMPLETED
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
University Hospital, Lille n=42
NCT04592809 COMPLETED
Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
University of Texas Southwestern Medical Center n=50
NCT07253207 COMPLETED
Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder
Zhejiang Huahai Pharmaceutical Co., Ltd. n=392
NCT06029426 COMPLETED
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Neumora Therapeutics, Inc. n=383
NCT05455684 COMPLETED
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Janssen Research & Development, LLC n=513
NCT04855747 TERMINATED
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Levomecor Inc. n=236
NCT06011577 TERMINATED
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
Levomecor Inc. n=27
NCT03421808 COMPLETED
EEG Synchronized TMS Trial for Depression
Medical University of South Carolina n=34
NCT05061719 COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=812
NCT06048263 WITHDRAWN
The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series
Washington University School of Medicine
NCT02942004 COMPLETED
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Supernus Pharmaceuticals, Inc. n=138
NCT03665038 COMPLETED
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Supernus Pharmaceuticals, Inc. n=28
NCT02942017 COMPLETED
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Supernus Pharmaceuticals, Inc. n=108
NCT04513912 COMPLETED
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Janssen Research & Development, LLC n=757
NCT03053362 COMPLETED
THINC-it Vortioxetine - Sensitivity to Change
Brain and Cognition Discovery Foundation n=158
NCT04532749 TERMINATED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Janssen Research & Development, LLC n=212
NCT03231358 COMPLETED
Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
Brown University n=1,758
NCT04260607 TERMINATED
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department
Naval Medical Center Camp Lejeune n=1
NCT04973930 SUSPENDED
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
New York State Psychiatric Institute n=20
NCT05061706 COMPLETED
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=480
NCT04985942 COMPLETED
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=485
NCT05391555 COMPLETED
Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
University of California, San Francisco n=10
NCT04338321 COMPLETED
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
Janssen-Cilag International NV n=676
NCT02417064 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=346
NCT02418585 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=236
NCT03039192 COMPLETED
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Janssen Research & Development, LLC n=226
NCT03097133 COMPLETED
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Janssen Research & Development, LLC n=230
NCT03434041 COMPLETED
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=252
NCT02497287 COMPLETED
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Janssen Research & Development, LLC n=802
NCT02422186 COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=139
NCT02493868 COMPLETED
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC n=719
NCT02782104 COMPLETED
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Janssen Research & Development, LLC n=1,148
NCT03852160 WITHDRAWN
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Janssen-Cilag International NV
NCT03693105 TERMINATED
The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition
Magnus Medical n=2
NCT04285515 COMPLETED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Intra-Cellular Therapies, Inc. n=488
NCT05227209 TERMINATED
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
Sumitomo Pharma America, Inc. n=64
NCT04939649 COMPLETED
Ketamine As an Adjunctive Therapy for Major Depression (2)
University of Dublin, Trinity College n=63
NCT04855760 COMPLETED
Safety of REL-1017 for Major Depressive Disorder
Relmada Therapeutics, Inc. n=627
NCT06735079 WITHDRAWN
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
MGGM LLC
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT06717724 COMPLETED
§ Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis
Sf Luca Chronic Disease Hospital n=203
NCT04504253 COMPLETED
A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
University of Utah n=18
NCT05169710 TERMINATED
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
Sumitomo Pharma America, Inc. n=83
NCT04688164 COMPLETED
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Relmada Therapeutics, Inc. n=227
NCT03864614 COMPLETED
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
Biogen n=1,515
NCT03697603 COMPLETED
A Study of Brexpiprazole in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=740
NCT03909217 COMPLETED
Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).
The University of Hong Kong n=470
NCT01928446 TERMINATED
Lithium for Suicidal Behavior in Mood Disorders
VA Office of Research and Development n=519
NCT03737474 COMPLETED
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=248
NCT05081167 COMPLETED
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Relmada Therapeutics, Inc. n=232
NCT04345471 COMPLETED
A Study of MD-120 in Patients With Depression
Mochida Pharmaceutical Company, Ltd. n=615
NCT02529462 COMPLETED
Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients
AB Biotics, SA n=521
NCT04442490 COMPLETED
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
Biogen n=543
NCT04476030 COMPLETED
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
Biogen n=440
NCT02978326 COMPLETED
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
Biogen n=276
NCT04442503 COMPLETED
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
Biogen n=200
NCT04007367 TERMINATED
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
Biogen n=53
NCT03672175 COMPLETED
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
Biogen n=581
NCT03771664 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
Biogen n=87
NCT04603781 SUSPENDED
CBD Oil for Reducing Emotional Impact of COVID-19
University of Texas at Austin n=200
NCT05427981 WITHDRAWN
Anti-suicidal Effects of Buprenorphine In Depressed Individuals
New York State Psychiatric Institute
NCT03538691 COMPLETED
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,149
NCT03573297 COMPLETED
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
AbbVie n=901
NCT03113968 COMPLETED
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Bo Hu n=403
NCT04476446 COMPLETED
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
Janssen-Cilag, S.A. n=41
NCT03674671 SUSPENDED
Ketamine Versus Electroconvulsive Therapy in Depression
University of Ottawa n=240
NCT05950061 COMPLETED
Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder
KRL Hospital, Islamabad n=744
NCT03485274 COMPLETED
Substance Misuse To Psychiatric Disorders for Cannabis
The University of Hong Kong n=37
NCT05482672 WITHDRAWN
GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression
Cale Andrew Jacobs, PhD
NCT03889756 TERMINATED
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
Yale University n=3
NCT03105245 COMPLETED
Understanding How Anaesthesia Affects ECT Outcomes
The University of New South Wales n=54
NCT04162522 COMPLETED
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
University Health Network, Toronto n=1
NCT03539887 COMPLETED
Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
The University of Texas Health Science Center, Houston n=33
NCT04227704 COMPLETED
Ketamine to Prevent PPD After Cesarean
Washington University School of Medicine n=25
NCT04383691 TERMINATED
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
Sumitomo Pharma (Suzhou) Co., Ltd. n=124
NCT05014919 TERMINATED
Vortioxetine to Prevent Return of Symptoms in Children With Depression
H. Lundbeck A/S n=35
NCT02871297 TERMINATED
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
H. Lundbeck A/S n=662
NCT02674529 COMPLETED
Study of Neural Responses Induced by Antidepressant Effects
Marta Peciña, MD PhD n=60
NCT03738215 COMPLETED
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
AbbVie n=759
NCT04019704 COMPLETED
A Trial of AXS-05 in Patients With Major Depressive Disorder
Axsome Therapeutics, Inc. n=327
NCT04039022 COMPLETED
Open-Label Safety Study of AXS-05 in Subjects With Depression
Axsome Therapeutics, Inc. n=876
NCT02709655 COMPLETED
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
H. Lundbeck A/S n=683
NCT03739203 COMPLETED
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
AbbVie n=752
NCT04832425 COMPLETED
A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
Praxis Precision Medicines n=216
NCT02532660 TERMINATED
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode
Laboratório Catarinense SA n=111
NCT02553915 COMPLETED
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
Massachusetts General Hospital n=61
NCT01312922 COMPLETED
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
PharmaNeuroBoost N.V. n=555
NCT04000009 TERMINATED
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
ACADIA Pharmaceuticals Inc. n=235
NCT02624102 COMPLETED
Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression
Hemanny, Curt, M.D. n=76
NCT03569475 COMPLETED
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
Allergan n=501
NCT04405791 COMPLETED
Efficacy of Clinical Application of Transcranial Low Intensity Focused Ultrasonic Stimulation for Patients With Major Deperessive Disorder - Exploratory Clinical Trial
Gangnam Severance Hospital n=30
NCT02726659 TERMINATED
Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=1
NCT02556606 COMPLETED
Ketamine for Treatment Resistant Late-Life Depression
VA Office of Research and Development n=33
NCT01123707 TERMINATED
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=173
NCT01111565 TERMINATED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=137
NCT04364997 COMPLETED
Study of Desvenlafaxine in Treating Major Depressive Disorder.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=420
NCT03968159 COMPLETED
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
ACADIA Pharmaceuticals Inc. n=298
NCT04853407 COMPLETED
A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Luye Pharma Group Ltd. n=558
NCT01111552 TERMINATED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=237
NCT01111539 TERMINATED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=211
NCT03435744 COMPLETED
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.
Pakistan Institute of Living and Learning n=150
NCT02987985 COMPLETED
Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy
University of Saskatchewan n=50
NCT03610048 TERMINATED
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
Alkermes, Inc. n=175
NCT03108625 COMPLETED
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
H. Lundbeck A/S n=94
NCT03395353 TERMINATED
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Shionogi n=151
NCT01436175 TERMINATED
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
Shire n=1,570
NCT01436149 COMPLETED
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Shire n=1,262
NCT01436162 COMPLETED
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Shire n=1,105
NCT03026426 COMPLETED
Effectiveness of a mHealth Intervention for the Treatment of Depression in People With Diabetes or Hypertension in Peru
Universidad Peruana Cayetano Heredia n=432
NCT03188185 COMPLETED
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
Alkermes, Inc. n=278
NCT02389816 COMPLETED
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
Takeda n=493
NCT02741791 COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
Axsome Therapeutics, Inc. n=312
NCT03652948 COMPLETED
Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults
Palo Alto Veterans Institute for Research n=70
NCT02535572 COMPLETED
Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment
Medical University of South Carolina n=48
NCT01441440 COMPLETED
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=538
NCT01485887 COMPLETED
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=50
NCT04091139 COMPLETED
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
Chinese University of Hong Kong n=27
NCT04216888 COMPLETED
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
Dan Iosifescu n=9
NCT03315793 COMPLETED
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
Shionogi n=149
NCT03487198 TERMINATED
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
Otsuka Beijing Research Institute n=65
NCT01110902 COMPLETED
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
Novartis Pharmaceuticals n=589
NCT01156415 TERMINATED
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
Novartis Pharmaceuticals n=837
NCT01110889 COMPLETED
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
Novartis Pharmaceuticals n=582
NCT03614156 TERMINATED
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc n=363
NCT04393818 COMPLETED
Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19
Fundació d'investigació Sanitària de les Illes Balears n=560
NCT02686333 COMPLETED
Meditation for Depression and Anxiety Symptoms in Dialysis Patients
Lady Davis Institute n=50
NCT02431806 COMPLETED
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Forest Laboratories n=552
NCT03560518 TERMINATED
Study of Rapastinel as Monotherapy in Patients With MDD
Naurex, Inc, an affiliate of Allergan plc n=439
NCT02709746 COMPLETED
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
H. Lundbeck A/S n=784
NCT02044211 COMPLETED
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
University of Pittsburgh n=756
NCT01482806 COMPLETED
Online Treatments for Mood and Anxiety Disorders in Primary Care
University of Pittsburgh n=700
NCT01602211 COMPLETED
INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant
Fred Hutchinson Cancer Center n=1,600
NCT02988076 SUSPENDED
Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression
MYnd Analytics n=468
NCT03675776 TERMINATED
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc n=50
NCT03668600 TERMINATED
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc n=230
NCT03002077 COMPLETED
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Naurex, Inc, an affiliate of Allergan plc n=617
NCT00641108 COMPLETED
Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression
University of Pennsylvania n=30
NCT04315597 COMPLETED
Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
Bayer n=398
NCT02452060 COMPLETED
Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy
NYU Langone Health n=90
NCT02951988 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
Naurex, Inc, an affiliate of Allergan plc n=1,304
NCT02191397 COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
GlaxoSmithKline n=534
NCT03436121 WITHDRAWN
Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department
Maria Pacella
NCT01085812 COMPLETED
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
Forest Laboratories n=734
NCT04216095 COMPLETED
Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder
Tanta University n=60
NCT02943564 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
Naurex, Inc, an affiliate of Allergan plc n=658
NCT01878292 COMPLETED
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Forest Laboratories n=529
NCT02659085 COMPLETED
Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder
Pouya Movahed Rad n=198
NCT02943577 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
Naurex, Inc, an affiliate of Allergan plc n=429
NCT02932943 COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Naurex, Inc, an affiliate of Allergan plc n=465
NCT01687478 TERMINATED
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
Eli Lilly and Company n=176
NCT02372799 COMPLETED
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
Forest Laboratories n=473
NCT01506492 COMPLETED
Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients
University Health Network, Toronto n=305
NCT00696137 COMPLETED
Long-term Extension Study of BEMA™ Fentanyl
BioDelivery Sciences International n=5
NCT02436239 COMPLETED
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
Forest Laboratories n=330
NCT02418702 WITHDRAWN
A Study to Decrease Suicidal Thinking Using Ketamine
United States Naval Medical Center, San Diego
NCT01715805 COMPLETED
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
Forest Laboratories n=1,022
NCT01838876 COMPLETED
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
Forest Laboratories n=442
NCT02720198 COMPLETED
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
Duke University n=60
NCT02085135 COMPLETED
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Alkermes, Inc. n=66
NCT02218008 COMPLETED
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Alkermes, Inc. n=407
NCT02158533 COMPLETED
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Alkermes, Inc. n=385
NCT02703363 COMPLETED
Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression
Pakistan Institute of Living and Learning n=265
NCT02358343 COMPLETED
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
University of Washington n=184
NCT03855865 WITHDRAWN
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
Naurex, Inc, an affiliate of Allergan plc
NCT02158546 COMPLETED
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
Alkermes, Inc. n=447
NCT02838043 COMPLETED
The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients
Queen's University n=10
NCT01342536 COMPLETED
African American Depression Intervention Trial (AADI)
University of Wisconsin, Madison n=160
NCT02466087 COMPLETED
Role of Magnesium Supplementation in the Treatment of Depression
University of Vermont n=126
NCT00965497 COMPLETED
Escitalopram (Lexapro) for Depression MS or ALS
University of South Carolina n=13
NCT02583867 COMPLETED
Predictors of Depression Treatment Response to Exercise
University of Texas Southwestern Medical Center n=38
NCT02670538 COMPLETED
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Forest Laboratories n=493
NCT02670551 COMPLETED
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
Forest Laboratories n=488
NCT01372150 COMPLETED
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Pfizer n=340
NCT02451293 COMPLETED
The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome
Zealand University Hospital n=252
NCT00831415 COMPLETED
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
Pfizer n=304
NCT01370499 COMPLETED
A Study of LY2216684 in Participants With Major Depression Disorder
Eli Lilly and Company n=288
NCT01944969 TERMINATED
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
H. Lundbeck A/S n=26
NCT01837797 TERMINATED
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
H. Lundbeck A/S n=129
NCT00578669 COMPLETED
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
Butler Hospital n=206
NCT02846662 COMPLETED
Effectiveness of a Mobile Technology Intervention for the Treatment of Depression
University of Sao Paulo General Hospital n=880
NCT01121536 TERMINATED
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cephalon n=867
NCT01360866 COMPLETED
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=2,944
NCT02367521 COMPLETED
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)
Johns Hopkins University n=70
NCT02196506 COMPLETED
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Otsuka Pharmaceutical Development & Commercialization, Inc. n=837
NCT02800226 COMPLETED
Pilot Study Comparing 10hz vs Theta Burst Stimulation
University of British Columbia n=20
NCT01138007 COMPLETED
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
GlaxoSmithKline n=572
NCT00914680 COMPLETED
Berlin Magnetic Seizure Therapy Depression Trial 01
Charite University, Berlin, Germany n=32
NCT01945047 COMPLETED
Action of Ketamine in Treatment-Resistant Depression
University of Ottawa n=46
NCT01727726 COMPLETED
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
Otsuka Pharmaceutical Development & Commercialization, Inc. n=2,182
NCT01421342 COMPLETED
VA Augmentation and Switching Treatments for Improving Depression Outcomes
VA Office of Research and Development n=1,522
NCT02046564 COMPLETED
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=412
NCT02057406 COMPLETED
Omega 3 for Treatment of Depression in Patients With Heart Failure
Wei Jiang n=108
NCT01655706 COMPLETED
Canadian Biomarker Integration Network for Depression Study
University Health Network, Toronto n=211
NCT01185340 COMPLETED
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Eli Lilly and Company n=1,056
NCT01187407 COMPLETED
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Eli Lilly and Company n=1,480
NCT01155661 COMPLETED
A Safety Study in Participants With Major Depressive Disorder
Eli Lilly and Company n=608
NCT01299272 COMPLETED
A Study in Prevention of Re-emergence of Depression Symptoms
Eli Lilly and Company n=1,249
NCT01173601 COMPLETED
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Eli Lilly and Company n=1,416
NCT00795821 COMPLETED
A Study in Adult Patients With Major Depressive Disorder
Eli Lilly and Company n=495
NCT00946998 COMPLETED
Chronic Kidney Disease Antidepressant Sertraline Trial
VA Office of Research and Development n=201
NCT01407575 COMPLETED
Buprenorphine for Treatment Resistant Depression
University of Pittsburgh n=13
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT02507219 COMPLETED
Study of Ibuprofen Effects on Brain Function
Laureate Institute for Brain Research, Inc. n=24
NCT01098318 COMPLETED
Rhodiola Rosea Therapy of Major Depressive Disorder
University of Pennsylvania n=58
NCT01803711 TERMINATED
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
UConn Health n=6
NCT02166424 COMPLETED
The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)
Tokyo Medical University n=108
NCT02308956 COMPLETED
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
University of Cape Town n=324
NCT01139060 COMPLETED
Organized Self-Management Support Services for Chronic Depression
Kaiser Permanente n=302
NCT02072187 TERMINATED
Adjunctive Vitamin D in the Treatment of Non-remitted Depression
START Clinic for Mood and Anxiety Disorders n=9
NCT00849901 COMPLETED
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Eli Lilly and Company n=337
NCT01308814 COMPLETED
Perimenopausal Estrogen Replacement Therapy Study
University of North Carolina, Chapel Hill n=172
NCT02400346 COMPLETED
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
H. Lundbeck A/S n=132
NCT01838681 COMPLETED
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
H. Lundbeck A/S n=1,986
NCT01371708 COMPLETED
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
Pfizer n=283
NCT00683852 COMPLETED
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Massachusetts General Hospital n=225
NCT00637494 TERMINATED
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Corcept Therapeutics n=292
NCT02279953 COMPLETED
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
H. Lundbeck A/S n=151
NCT00711971 COMPLETED
Does Fish Oil Prevent Depression in Pregnancy and Postpartum?
University of Michigan n=126
NCT00981383 COMPLETED
Treating Depression in Coronary Artery Disease With Omega-3 Fatty Acids
Sunnybrook Health Sciences Centre n=92
NCT01371734 COMPLETED
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Pfizer n=363
NCT02272517 COMPLETED
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
H. Lundbeck A/S n=101
NCT02279966 COMPLETED
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
H. Lundbeck A/S n=152
NCT01557712 COMPLETED
Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
University Hospital, Grenoble n=25
NCT01371721 COMPLETED
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Pfizer n=269
NCT00866294 COMPLETED
Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
GlaxoSmithKline n=416
NCT02657980 COMPLETED
The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder
Ybrain Inc. n=96
NCT01890083 TERMINATED
A Health Intervention to Prevent Depression Hepatitis C Patients
University of Texas Southwestern Medical Center n=1
NCT00868374 TERMINATED
Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
Keming Gao n=23
NCT01403662 COMPLETED
Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression
University Health Network, Toronto n=29
NCT01894815 COMPLETED
Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
University of Sao Paulo n=245
NCT02152878 COMPLETED
Transcranial Direct Current Stimulation for the Treatment of Bipolar Depression
University of Sao Paulo n=60
NCT02961738 COMPLETED
Is Narrative Reformulation During Cognitive Analytic Therapy Helpful?
University of Sheffield n=95
NCT01667822 COMPLETED
Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy
Karolinska Institutet n=396
NCT02845349 WITHDRAWN
Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)
Johns Hopkins University
NCT01040208 TERMINATED
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
Sprout Pharmaceuticals, Inc n=111
NCT01421134 COMPLETED
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Sumitomo Pharma America, Inc. n=211
NCT02212613 WITHDRAWN
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT01464463 COMPLETED
The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major Depression
Philipps University Marburg n=200
NCT01401569 TERMINATED
Efficacy of Exercise and Counseling Intervention on Relapse in Smoker With Depressive Disorders
University Hospital, Montpellier n=70
NCT00629551 COMPLETED
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
Sanofi n=825
NCT01305408 COMPLETED
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cephalon n=399
NCT02423824 COMPLETED
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
University Health Network, Toronto n=21
NCT01955538 COMPLETED
The Effect of BAT Versus Mixed Physical Activity as add-on Treatment for Traumatised Refugees.
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital n=338
NCT01072630 COMPLETED
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cephalon n=492
NCT01072929 COMPLETED
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Cephalon n=433
NCT01423253 COMPLETED
Major Depressive Disorder With Mixed Features - Extension
Sumitomo Pharma America, Inc. n=48
NCT01652001 COMPLETED
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Universidad de Granada n=185
NCT02013531 COMPLETED
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Otsuka Pharmaceutical Development & Commercialization, Inc. n=37
NCT01386086 COMPLETED
Aripiprazole and Resistant Postpartum Depression
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=10
NCT01942785 COMPLETED
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
H. Lundbeck A/S n=55
NCT01667809 COMPLETED
CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care
Karolinska Institutet n=5
NCT01636791 COMPLETED
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
Karolinska Institutet n=211
NCT01685294 COMPLETED
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
Brown University n=181
NCT01360632 COMPLETED
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,539
NCT02086929 COMPLETED
Trazodone Once a Day in Major Depression Disorder
Aziende Chimiche Riunite Angelini Francesco S.p.A n=364
NCT02012218 COMPLETED
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
Otsuka Pharmaceutical Development & Commercialization, Inc. n=61
NCT01594606 COMPLETED
Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth
Wayne State University n=150
NCT01318434 COMPLETED
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Euthymics BioScience, Inc. n=342
NCT02443194 TERMINATED
The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
michal roll n=50
NCT01562184 COMPLETED
Investigating tDCS as a Treatment for Unipolar and Bipolar Depression
The University of New South Wales n=120
NCT01360645 COMPLETED
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Otsuka Pharmaceutical Development & Commercialization, Inc. n=826
NCT01808651 COMPLETED
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
Eli Lilly and Company n=200
NCT00902330 COMPLETED
Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
Virginia Commonwealth University n=161
NCT01370733 COMPLETED
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Wave Neuroscience n=202
NCT02565316 COMPLETED
Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial
Shiraz University of Medical Sciences n=70
NCT01353092 COMPLETED
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
Hillerod Hospital, Denmark n=65
NCT02099890 COMPLETED
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
Brock University n=20
NCT01428661 COMPLETED
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
Vanda Pharmaceuticals n=507
NCT01409317 COMPLETED
Neural Predictors and Longitudinal Neural Correlates of Deep Transcranial Magnetic Stimulation for Treating Major Depression
Douglas Mental Health University Institute n=10
NCT01808612 COMPLETED
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
Eli Lilly and Company n=513
NCT00373698 COMPLETED
Re-Engineering Systems for the Primary Care Treatment for PTSD
US Department of Veterans Affairs n=195
NCT02015546 COMPLETED
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
Duke University n=70
NCT00570050 COMPLETED
Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder
University Health Network, Toronto n=35
NCT01545414 COMPLETED
Internet-CBT (Cognitive Behavioral Therapy) for Depression and Anxiety in Parkinsons Disease
Karolinska Institutet n=150
NCT01527786 COMPLETED
Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine
BC Women's Hospital & Health Centre n=25
NCT00621842 COMPLETED
Lamotrigine for Symptoms of Geriatric Bipolar Depression
University Hospitals Cleveland Medical Center n=57
NCT01145872 COMPLETED
The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
University of Denver n=92
NCT00887224 COMPLETED
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Pfizer n=874
NCT00769015 COMPLETED
Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Thomas Jefferson University n=188
NCT01355081 COMPLETED
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
Takeda n=366
NCT01524497 COMPLETED
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Lee's Pharmaceutical Limited n=382
NCT01571453 COMPLETED
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
H. Lundbeck A/S n=437
NCT02125799 COMPLETED
Accelerated rTMS for Treatment-Resistant Major Depression
Douglas Mental Health University Institute n=20
NCT01443715 COMPLETED
A Stepped Care Model of Adolescent Depression Treatment in Primary Care
New York State Psychiatric Institute n=48
NCT01447602 COMPLETED
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
New York State Psychiatric Institute n=10
NCT01422213 COMPLETED
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
H. Lundbeck A/S n=598
NCT01375920 COMPLETED
Antiglucocorticoid Augmentation of antiDepressants in Depression
Jane Barnes n=190
NCT00958204 COMPLETED
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
University of British Columbia n=134
NCT01152996 COMPLETED
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
Takeda n=1,075
NCT01355523 TERMINATED
The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients
Melissa Voigt Hansen n=54
NCT01180400 COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
AstraZeneca n=295
NCT01157078 COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
AstraZeneca n=319
NCT01153347 COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
AstraZeneca n=2,409
NCT01197508 COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
AstraZeneca n=696
NCT01152554 COMPLETED
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
AstraZeneca n=813
NCT00694304 COMPLETED
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
H. Lundbeck A/S n=535
NCT00958568 COMPLETED
A Study in Relapse Prevention of Treatment-Resistant Depression
Eli Lilly and Company n=892
NCT01488071 COMPLETED
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
H. Lundbeck A/S n=495
NCT00904891 COMPLETED
Testing the Effectiveness of Adolescent Depression Prevention Programs (The OregonBlues Study)
Oregon Research Institute n=390
NCT01131559 TERMINATED
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
Lindner Center of HOPE n=50
NCT01140906 COMPLETED
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
H. Lundbeck A/S n=607
NCT01323478 COMPLETED
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
H. Lundbeck A/S n=71
NCT00635219 COMPLETED
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
H. Lundbeck A/S n=766
NCT00876343 COMPLETED
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=586
NCT00882362 COMPLETED
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
Otsuka Pharmaceutical Co., Ltd. n=155
NCT00811252 COMPLETED
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
H. Lundbeck A/S n=453
NCT01363310 TERMINATED
The Quietude Study: Quetiapine Use for Agitated Depression
Physicians Research And Education Network n=250
NCT00735709 COMPLETED
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Takeda n=560
NCT01255787 COMPLETED
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
Takeda n=600
NCT01153009 COMPLETED
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Takeda n=614
NCT01163266 COMPLETED
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Takeda n=462
NCT01179516 COMPLETED
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Takeda n=469
NCT00672620 COMPLETED
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
Takeda n=611
NCT00672958 COMPLETED
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
Takeda n=600
NCT00707980 COMPLETED
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Takeda n=836
NCT01395147 COMPLETED
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
Takeda n=119
NCT01377194 COMPLETED
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
Forest Laboratories n=568
NCT00969709 COMPLETED
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Forest Laboratories n=724
NCT00969150 COMPLETED
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Forest Laboratories n=362
NCT01034462 COMPLETED
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
Forest Laboratories n=442
NCT01203683 COMPLETED
Testing the Effectiveness of a Computer-based Program for Depression
University of Texas at Austin n=53
NCT01957319 COMPLETED
Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability
University of Catania n=72
NCT00769769 COMPLETED
Comparing Delivery Methods of Cognitive Behavioral Therapy for Depressed African-American Dementia Caregivers
Robert L. Glueckauf n=106
NCT00714090 COMPLETED
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Club rTMS et Psychiatrie n=170
NCT01153139 COMPLETED
Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression
University Hospital Tuebingen n=32
NCT01021384 COMPLETED
Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders
Boston Medical Center n=122
NCT00866593 COMPLETED
A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression
Shanghai Mental Health Center n=260
NCT00953108 COMPLETED
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
Ludwig-Maximilians - University of Munich n=60
NCT00751504 COMPLETED
Quetiapine in the Treatment of Psychotic Depression - a Pilot Study
Ruhr University of Bochum n=16
NCT01409304 COMPLETED
Effectiveness of Deep Transcranial Magnetic Stimulation in Depression
Douglas Mental Health University Institute n=18
NCT01228890 WITHDRAWN
Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)
University of Chicago
NCT01727635 COMPLETED
The Long-term Effects of Body-mind-spirit Group Therapy
National Taiwan University Hospital n=60
NCT01034267 COMPLETED
Safety Study of F2695 SR in Major Depressive Disorder
Forest Laboratories n=828
NCT00511680 COMPLETED
Beat the Blues: Treating Depression in African American Elders
Thomas Jefferson University n=192
NCT01178255 TERMINATED
Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)
Charite University, Berlin, Germany n=44
NCT00789854 COMPLETED
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
AstraZeneca n=688
NCT01109030 COMPLETED
Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder
Tehran University of Medical Sciences n=50
NCT00849693 COMPLETED
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Eli Lilly and Company n=463
NCT01149213 COMPLETED
Follow-up Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder
University of Sao Paulo n=42
NCT00885014 COMPLETED
Telephone Cognitive-Behavioral Therapy (CBT) for Subthreshold Depression and Presenteeism in Workplace
Kyoto University n=118
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT00929409 TERMINATED
Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia
Norwegian University of Science and Technology n=30
NCT01149889 COMPLETED
Transcranial Direct Current Stimulation to Treat Major Depressive Disorder
University of Sao Paulo n=60
NCT01033084 COMPLETED
Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder
University of Sao Paulo n=120
NCT00798707 COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
Pfizer n=709
NCT00488670 TERMINATED
Escitalopram and Depression in Elderly Alzheimer's Patients
University of British Columbia n=50
NCT00863798 COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer n=682
NCT00763230 COMPLETED
A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression
The University of New South Wales n=68
NCT00824291 COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer n=437
NCT01108016 COMPLETED
Expanding Rural Access: Distance Delivery of Support Groups (Main Study)
Stanford University n=100
NCT00683592 COMPLETED
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
Forest Laboratories n=481
NCT00668525 COMPLETED
Escitalopram in Adult Patients With Major Depressive Disorder
Forest Laboratories n=877
NCT00610259 COMPLETED
Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia
Nagoya City University n=40
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only